肾上腺素(Adrenaline) - 药物靶点：adrenergic receptor_在研适应症：间歇性哮喘，瞳孔散大，超敏反应_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Adrenaline (JP17)、Adrenaline Hydrochlaride、Adrenaline Hydrochloride

+ [54]

靶点

adrenergic receptor

作用方式

激动剂

作用机制

adrenergic receptor激动剂(肾上腺素能受体家族激动剂)

治疗领域

免疫系统疾病神经系统疾病心血管疾病+ [4]

在研适应症

间歇性哮喘瞳孔散大超敏反应+ [11]

非在研适应症

呼吸道感染过敏性鼻炎

原研机构

Medeca Pharma AB

在研机构

ALK-Abello A/SARS Pharmaceuticals, Inc.

Daiichi Sankyo Co., Ltd.

+ [18]

非在研机构

Amphastar Pharmaceuticals, Inc.

Nxera Pharma Co., Ltd.

Shin Nippon Biomedical Laboratories, Ltd.

+ [2]

权益机构

ARS Pharmaceuticals, Inc.Sandoz, Inc.

G2B Pharma, Inc.

+ [8]

最高研发阶段批准上市

首次获批日期

美国 (1967-11-08),

哮喘

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、优先审评 (美国)

登录后查看时间轴

结构/序列

分子式C9H13NO3

InChIKeyUCTWMZQNUQWSLP-VIFPVBQESA-N

CAS号51-43-4

关联

323

项与肾上腺素相关的临床试验

NCT07084753

/ Not yet recruitingN/AIIT

Comparison of Opioid-based Anesthesia, Opioid-free Anesthesia Based on Intravenous Drugs and Opioid-free Anesthesia With Thoracic Paravertebral Block, in Patients Undergoing Laparoscopic Gastric Bypass Surgery for Obesity

Regional anesthesia is a technique in which a local anesthetic is injected near a nerve or spinal cord to block sensation, motor stimulation, and pain. In this study, an ultrasound-guided paravertebral block will be used, with careful consideration of all positive and negative factors and possible complications. A thoracic paravertebral block is performed by inserting a needle into the intercostal spaces on the back, approximately 4 cm lateral to the spine. Many studies support excellent pain control with this technique, during and after surgery in thoracic and abdominal surgery. Investigators aim to achieve faster patient mobility after surgery, rapid recovery of bowel function, reduced nausea and vomiting, and maximum pain control. The use of opioids, which can additionally cause respiratory suppression and drowsiness, is avoided.
At any time in case of need to switch from laparoscopic to open surgery, equally adequate anesthesia and postoperative analgesia are ensured without the need to change the approach to the same. In this study, the basic scientific assumption (hypothesis) of the researchers is that non-opioid anesthesia with thoracic paravertebral block provides adequate pain control during and long-term after the surgical procedure, without the side effects of opioid anesthesia.
The main goal of the study is to determine which type of anesthesia results in the best pain control and most significantly reduces complications of anesthesia and surgery in overweight patients who are scheduled for laparoscopic longitudinal gastrectomy and partial/total gastrectomy.

开始日期2025-07-30

申办/合作机构

University Hospital Dubrava

NCT07038746

/ Not yet recruiting临床1期IIT

A Phase 1b, Open-Label, Exploratory Study Evaluating the Effects of Inhaled Epinephrine in Individuals Experiencing Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges

The goal of this exploratory study is to evaluate the effects of inhaled epinephrine in subjects, who may not be eligible for the GHL-101 trial, and who are experiencing systemic allergic reaction (SAR) that occur following allergy testing, subcutaneous immunotherapy (SCIT), oral challenges (with food and/or drug) or oral immunotherapy (OIT).

开始日期2025-07-01

申办/合作机构

Kokua Pharma Inc

NCT07073209

/ Not yet recruitingN/AIIT

PENG vs Femoral Block for Hip Fracture, A Pragmatic Cluster-Randomized Study

This study aims to compare the Pericapsular Nerve Group (PENG) block with femoral block for hip fracture pain. Participants presenting to the hospital with a diagnosis of hip fracture and consenting to analgesic block will receive either a PENG or femoral block. The choice of block will be dictated by a randomized monthly schedule, and all participants presenting during each four-week period will receive the designated block. A sub-group analysis will be performed to determine any difference in efficacy in participants with intracapsular versus extracapsular fractures.

开始日期2025-07-01

申办/合作机构

Weill Medical College of Cornell University

100 项与肾上腺素相关的临床结果

登录后查看更多信息

100 项与肾上腺素相关的转化医学

登录后查看更多信息

100 项与肾上腺素相关的专利（医药）

登录后查看更多信息

46,751

项与肾上腺素相关的文献（医药）

2025-12-31·SCANDINAVIAN CARDIOVASCULAR JOURNAL

Ex vivo resuscitation and evaluation of hearts after 22 minutes of normothermic cardiac arrest

Article

作者: Li, Mei ; Steen, Erik ; Steen, Stig ; Pascevivius, Audrius ; Liao, Qiuming

OBJECTIVE:

The aim was to resuscitate and evaluate hearts ex vivo after 22 min of cardiac arrest with the goal of increasing the number of usable hearts from controlled donation after circulatory death (cDCD).

DESIGN:

Eight pigs (39-61 kg) underwent 22 min of ventricular fibrillation, after which the heart was first perfused in vivo for three minutes with an oxygenated, erythrocyte-containing cardioplegic preservation solution. The heart was then explanted and perfused ex vivo with the same solution for three hours at 18 °C in a transportable heart preservation system. Functional evaluation was performed ex vivo (n = 7), while one heart underwent orthotopic transplantation and was monitored for 24 h.

RESULTS:

The seven hearts evaluated ex vivo easily pumped twice the cardiac output measured in vivo. The transplanted heart maintained normal blood pressure, blood gases, and urine output throughout the 24-hour observation period. At the end of this period the aortic pressure was 104/80 mmHg with a heart rate of 129 beats per minute. Intravenous administration of 20, 40, and 100 µg adrenaline resulted in an aortic pressures of 238/171, 284/196, and 287/201 mmHg with corresponding heart rates of 162, 188, and 223 beats per minute.

CONCLUSION:

Hearts exposed to 22 min of cardiac arrest were successfully resuscitated ex vivo and demonstrated adequate function when evaluated.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations

Review

作者: Keene, Sharon A. ; Gupta, Aditya K. ; Talukder, Mesbah

Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.

2025-11-01·TALANTA

Synthesis of ternary heterostructured rice-stick-like Ag/polyoxometalates/nitrogen-doped carbon nanotube hybrids for the sensitive detection of adrenaline

Article

作者: Shen, Wei ; Yang, Xinjian ; Hao, Lin ; Zhang, Yufan ; Liu, Lin

This study presents the innovative design and synthesis of rice-stick-like Ag/polyoxometalates/nitrogen-doped carbon nanotubes (Ag/POM/N-CNTs) using an efficient and mild reduction method. N-CNTs are first synthesized through a self-degrading template method followed by the carbonization of polypyrrole nanotubes (PPy-NTs). The N-CNTs exhibit excellent characteristics, including a high length-to-diameter ratio and an interconnected nanotube structure, which shorten the electron transport distance and enhance electrochemical properties. During the process of loading Ag nanoparticles (Ag NPs) onto the N-CNTs, POM serves as both a reducing and linking agent. The synergistic effect between Ag species and N-CNTs significantly improves the catalytic performance of the nanohybrids. As a result, the Ag/POM/N-CNT-based electrochemical sensor demonstrates exceptional performance in adrenaline detection, with a broad linear range (0.40-700 μM), a low detection limit (0.30 μM, S/N = 3), and a sensitivity of 3.13 μA μM^-1. In addition to these advantages, the composite material also exhibits excellent specificity and stability, strongly indicating the practical application potential of Ag/POM/N-CNTs in adrenaline detection.

474

项与肾上腺素相关的新闻（医药）

2025-08-26

·GlobeNewswire-Health Care

Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony

TEL AVIV, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, proudly announced today that it had the honor of ringing the Closing Bell on Monday, 25 August, 2025, at the New York Stock Exchange (“NYSE”). This prestigious event marked a significant milestone in the Company’s journey to transform emergency medicine through needle-free, fast-acting intranasal therapies. Nasus Pharma’s executive team, board members, and key partners gathered on the NYSE podium to commemorate the Company’s progress and future ambitions. The ceremony recognized Nasus Pharma’s recent listing and celebrated the Company’s achievements in advancing its proprietary drug product candidates, designed to address critical unmet medical needs including severe allergic reactions and anaphylaxis. “We are honored to participate in this iconic tradition at the NYSE. This moment reflects the incredible dedication of our team and our commitment to developing potentially life-saving treatments,” said Dan Teleman, Chief Executive Officer. “At Nasus Pharma, our mission is grounded in innovation. Our proprietary intranasal powder technology aims to offer a fundamentally better way to deliver life-saving medications. This platform could have broad potential across emergency care, and we believe that we are just beginning to unlock it. At the center of everything we do is our care for patients. We are aiming to develop solutions that are fast, easy to use, and ready when they’re needed most, and currently focus on helping families who live with the fear of anaphylaxis every day who have to carry Epinephrine wherever they go, who worry about what could happen in a moment of exposure to allergens. That’s our purpose: to give families peace of mind, to give patients more accurate control, and to make a difference when seconds count.” A replay of the event can be found here and on Nasus Pharma’s Investor Relations Events page. About Nasus PharmaNasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. Forward Looking StatementsThis press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things: the development and commercialization, if any, of any other product candidates that we develop or may seek to develop, the potential of Nasus Pharma’s proprietary intranasal powder technology. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the initial public offering filed with the SEC on August 14, 2025. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Contactinfo@nasuspharma.comNasus Pharma Ltd. Israelhttps://www.nasuspharma.com Investor ContactMike MoyerLifeSci Advisors+1-617-308-4306mmoyer@lifesciadvisors.com

2025-08-21

·ir.alk.net

Six-month interim report (Q2) 2025 (unaudited)

ALK delivers 12% organic revenue growth with operating profit up 41% in Q2 Q2 results exceeded expectations, driven by an improved momentum for tablets and adrenaline autoinjectors. Sales in Europe were ahead of plan, supporting 12% overall revenue growth, despite phasing of product shipments to International markets. The operating profit (EBIT) increased by 41%, and the full-year revenue outlook has been upgraded. Q2 performance highlights Comparative figures for Q2 2024 are shown in brackets. Growth rates are stated in local currencies (l.c.), unless otherwise indicated. Total revenue increased by 12% to DKK 1,527 million (1,374) on double-digit growth in Europe and North America, while growth in International markets was flattish due to phasing of product shipments. Tablet sales grew by 16% to DKK 831 million (716), driven largely by higher volumes. Europe and North America delivered growth of 17% and 32%, respectively, while International markets reported 9% growth. SCIT/SLIT-drops sales declined 1% to DKK 481 million (490) following lower product shipments to China. Sales of Other products and services increased by 30% to DKK 215 million (168). Anaphylaxis revenue grew by 56%, driven mainly by higher Jext® sales. Operating profit (EBIT) increased by 41% to DKK 375 million (264) with an EBIT margin of 25% (19%). Progress was attributable to sales growth, improved gross margin, and the impact from last year’s optimisation initiatives. Free cash flow of DKK 216 million (161) was mainly driven by higher earnings. Cash flow from investing activities was DKK 104 million (98). Financial highlights Allergy+ strategy highlights Initial market response to the ongoing market launches of the house dust mite tablet and the tree pollen allergy tablet for children exceeds expectations. The launches contributed modestly to tablet sales growth. The neffy®adrenaline nasal spray was launched in the first EU market, Germany, end-June and additional launches are planned for the second half-year. An approval was recently obtained in the important UK market. The new dedicated paediatric sales force in the USA has been fully onboarded, trained, and deployed in the field. Patient recruitment for the clinical phase 2 trial with the peanut allergy tablet has been completed ahead of target. 2025 full-year outlook On 12 August 2025, ALK upgraded the full-year outlook based on the better-than-expected performance in Q2 and an improved outlook for the remainder of the year: Revenue is now expected to grow by 12-14% in local currencies (previously: 9-13%), driven by growth in all sales regions and product lines. Growth will predominantly be attributable to higher volumes, as ALK expects to treat more patients with its allergy immunotherapy (AIT) and anaphylaxis products. The EBIT margin is still projected to improve by 5 percentage points to 25%, fuelled by revenue growth, gross margin improvements, and optimisations. Commenting on the Q2 results, CEO Peter Halling said: “Q2 marked a step change in the execution of key strategic growth initiatives, notably the rollout of our respiratory tablets for young children, the launch of the neffy® adrenaline spray, and the deployment of a dedicated paediatric sales force in the US. While these efforts are still at an early stage, they have started contributing to growth, and we expect their impact to increase from the second half-year onwards. This reinforces our confidence in our ability to deliver sustained, profitable growth by reaching more patients with evidence-based allergy and anaphylaxis solutions." Hørsholm, 21 August 2025 ALK-Abelló A/S For further information, contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525Media: Maiken Riise Andersen, tel. +45 5054 1434 ALK is hosting a conference call for analysts and investors at 1.30 p.m. (CEST) on 21 August 2025 at which Management will review the financial results and the outlook. The conference call will be audio cast on https://ir.alk.net where the relevant presentation will be available shortly before the call begins. To register for the conference call, please use this link and follow the registration instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist diamondpass@choruscall.com and/or check your spam filter. We advise you to register well in advance and to call in before 1.25 p.m. (CEST). Attachment Company release_13_25UK_210825_Q2 25 interim report

财报临床2期上市批准

2025-08-18

·Pharmaceutical Technology

Aquestive signs $75m agreement for launch of Anaphylm

Anaphylm will be used for treating type I allergic reactions. Credit: wisely/Shutterstock.com. Aquestive Therapeutics has made a strategic funding agreement worth $75m with RTW Investments to support the potential launch of Anaphylm (epinephrine) sublingual film, a matrix-based epinephrine prodrug product candidate. The funding will be accessible following US Food and Drug Administration (FDA) approval of Anaphylm and the fulfilment of specific refinancing and customary conditions related to the existing debt of the company. RTW will obtain a tiered single-digit percentage of annual net sales of the product in the US to treat type I allergic reactions, including anaphylaxis, subject to a cap. RTW Investments managing partner and chief investment officer Roderick Wong stated: “We are excited to support Aquestive, and today’s investment reflects our belief in the commercial prospects of Anaphylm as a rescue treatment for patients experiencing a severe allergic reaction, including anaphylaxis.” Anaphylm begins to dissolve upon contact, eliminating the need for water or swallowing during administration. Its packaging is thinner and smaller compared to a standard credit card, allowing for easy portability, and is engineered to withstand weather conditions such as rain and sunlight. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The product trade name for AQST-109 has received conditional approval from the FDA, with final approval dependent on its FDA endorsement. Aquestive CEO Dan Barber stated: “This financing provides critical capital that will support Aquestive Therapeutics through 2027, enabling us to successfully bring Anaphylm to market, if approved by the FDA, and deliver a new treatment option for patients in need. “We continue to believe Anaphylm, potentially the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, can transform how patients carry and access their rescue medication.” Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

上市批准加速审批

100 项与肾上腺素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00095	肾上腺素	C01CA24 B02BC09 S01EA01	DB00668

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
间歇性哮喘	美国	Armstrong Pharmaceuticals, Inc.	2018-11-07
瞳孔散大	美国	Ph Healthcare Services	2012-12-07
超敏反应	美国	Viatris Specialty LLC	1987-12-22
麻醉	日本	Daiichi Sankyo Co., Ltd.	1986-02-25
支气管痉挛	日本	Daiichi Sankyo Co., Ltd.	1986-02-25
出血	日本	Daiichi Sankyo Co., Ltd.	1986-02-25
低血压	日本	Daiichi Sankyo Co., Ltd.	1986-02-25
休克	日本	Daiichi Sankyo Co., Ltd.	1986-02-25
过敏	中国	远大医药集团	1981-01-01
心脏停搏	中国	远大医药集团	1981-01-01
哮喘	美国	Wyeth Consumer Healthcare LLC	1967-11-08

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
持续性哮喘	临床2期	美国	ARS Pharmaceuticals, Inc.	2022-07-28
荨麻疹	临床2期	美国	ARS Pharmaceuticals, Inc.	2022-07-28
速发型超敏反应	临床2期	加拿大	Aquestive Therapeutics, Inc.	2022-07-12
药物过敏反应	临床1期	瑞典	Orexo AB	2024-04-22
过敏性鼻炎	临床1期	中国	ARS Pharmaceuticals, Inc.	2023-03-17
过敏性鼻炎	临床1期	中国	祐儿医药科技（上海）有限公司	2023-03-17
呼吸道感染	临床1期	澳大利亚	ARS Pharmaceuticals, Inc.	2021-08-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02722746 (Pilot epinephrine dose-finding study, CTgov)	临床1/2期	镇痛 \| 低血压	66	Ropivacaine (Ropivacaine Only Control Group)	積襯繭鏇鑰餘齋膚遞繭: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165	-	2025-06-18
				Ropivacaine+Epinephrine (Ropivacaine + 2 mcg/mL Epinephrine)
CTIS2024-514037-38-00 (OX640-002, Company_Website) 人工标引	N/A	过敏性鼻炎	30	OX640	襯獵遞願鹽膚鬱窪鹹構(夢餘鑰餘淵願構網顧鹹) = Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. 積積壓鬱壓糧膚廠構醖 (遞網選範鏇餘鑰窪獵鏇 ) 更多	积极	2025-01-10
				0.3 mg intramuscular epinephrine
GlobeNewswire 人工标引	N/A	口腔过敏综合征	-	Anaphylm (with allergen exposure)	糧襯鹹餘鑰齋壓壓簾窪(簾網鏇窪選鬱窪網蓋範) = no significant differences found between Anaphylm PK results in subjects with and without allergen exposure. 構遞構蓋遞糧蓋遞齋鏇 (膚鬱鑰願製鹽製壓觸積 ) 达到更多	积极	2024-10-24
				Anaphylm (without allergen exposure)
NCT04207840 (Pubmed \| J Aerosol Med Pulm Drug Deliv)	临床4期	哮喘 \| 过敏	28	Epinephrine MDI	壓選顧網餘鑰繭築鏇鹽(範餘製廠蓋願襯壓築積) = 醖網壓糧簾網願觸積構鬱製築膚蓋鹽遞夢構繭 (網衊網糧蓋壓餘醖簾觸 )	积极	2024-08-29
				Epinephrine IM	壓選顧網餘鑰繭築鏇鹽(範餘製廠蓋願襯壓築積) = 夢膚窪壓鹽廠淵積壓廠鬱製築膚蓋鹽遞夢構繭 (網衊網糧蓋壓餘醖簾觸 )
NCT03126968 (PROPHET, CTgov)	临床2/3期	出血 \| 肺移植排斥反应 \| 咯血	66	Topical epinephrine (Prophylactic Topical Epinephrine)	築窪構觸願壓築選壓觸 = 夢壓衊窪壓憲糧簾構餘齋壓鹽觸築製鬱築鬱積 (醖鑰願膚襯築構鬱願鏇, 簾淵願廠襯顧鹽鹹範窪 ~ 艱襯壓齋壓淵鹹憲積鹽) 更多	-	2024-08-28
				Placebos (Placebo)	築窪構觸願壓築選壓觸 = 鹹獵齋製選顧顧製鹹艱齋壓鹽觸築製鬱築鬱積 (醖鑰願膚襯築構鬱願鏇, 糧網壓齋遞獵廠鏇廠網 ~ 觸築夢顧蓋製蓋鹽簾遞) 更多
GlobeNewswire 人工标引	N/A	超敏反应	36	Anaphylm™ (epinephrine) Sublingual Film	簾繭鬱選鏇顧觸範鹽壓(鬱衊蓋顧範糧廠鏇選選) = 憲憲鹹築鹽夢蓋顧遞製顧獵憲願糧鏇選製蓋鬱 (鹽衊觸觸繭鏇齋構範選 ) 达到	积极	2024-07-25
				Adrenalin manual intramuscular (IM) injection	簾繭鬱選鏇顧觸範鹽壓(鬱衊蓋顧範糧廠鏇選選) = 鬱憲醖艱餘憲範簾鏇繭顧獵憲願糧鏇選製蓋鬱 (鹽衊觸觸繭鏇齋構範選 ) 达到
NCT02722746 (Pilot epinephrine dose-finding study, Pubmed)	临床1/2期	低血压	-	Epidural ropivacaine 0.2% without epinephrine	夢襯淵憲淵鏇蓋窪獵範(餘窪淵壓構鏇簾顧繭範) = 壓鏇艱鹹鬱鹽選繭選製簾築構鏇願顧獵淵壓鏇 (糧築鹽夢繭餘鏇構淵夢 )	不佳	2024-07-11
				Epidural ropivacaine 0.2% + 2 µg/mL epinephrine	夢襯淵憲淵鏇蓋窪獵範(餘窪淵壓構鏇簾顧繭範) = 襯窪築廠淵範網窪願艱簾築構鏇願顧獵淵壓鏇 (糧築鹽夢繭餘鏇構淵夢 )
NCT05881915 (MD-245-2022, Pubmed)	N/A	低血压	98	Epinephrine infusion (0.03 mcg/kg/min)	觸簾網積築構範鹽顧膚(網齋築淵網顧壓衊壓衊) = 夢範觸膚鑰築壓鬱壓壓觸觸範壓鬱築鏇願範築 (憲築醖顧醖鑰夢憲鹽淵 )	积极	2024-05-25
				Phenylephrine infusion (0.4 mcg/kg/min)	觸簾網積築構範鹽顧膚(網齋築淵網顧壓衊壓衊) = 蓋壓窪範製廠餘齋顧積觸觸範壓鬱築鏇願範築 (憲築醖顧醖鑰夢憲鹽淵 )
GlobeNewswire 人工标引	临床3期	超敏反应	100	Anaphylm (single dosing part)	衊繭遞顧憲鹽衊網鹹鑰(鬱鏇積選餘餘築憲鏇窪) = 鏇範觸餘壓衊範鹹簾築艱窪鏇壓廠膚壓壓範簾 (築繭鹹淵簾鬱顧積憲網 ) 更多	积极	2024-03-14
				Anaphylm (repeat dosing part)	選齋繭膚築醖夢製廠繭(範夢觸窪壓願艱鏇顧選) = 淵積遞壓積衊壓窪醖鑰艱衊壓壓積淵廠繭鬱繭 (壓構艱淵餘範廠範繭製 ) 更多
JPRN-jRCT2031230143 (AAAAI 12024 \| AAAAI 22024) 人工标引	临床3期	超敏反应 \| 过敏	15	neffy 1.0mg	壓窪構鹹鏇願構淵簾淵(積製鹹選願壓淵鑰選壓) = 廠鬱繭醖淵構鹹壓鬱膚製觸壓願顧淵壓廠壓鹽 (構醖積鏇襯觸觸淵壓繭 ) 更多	积极	2024-02-24
				neffy 2.0mg	壓窪構鹹鏇願構淵簾淵(積製鹹選願壓淵鑰選壓) = 遞構鑰積遞願鹹築壓遞製觸壓願顧淵壓廠壓鹽 (構醖積鏇襯觸觸淵壓繭 ) 更多